Concert Pharmaceuticals Achieves $2M Milestone Collaborating With Avanir Pharmaceuticals

Concert Pharmaceuticals, Inc. (CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment... more →
Posted in: Press